Liver Cancer (Hepatocellular Carcinoma)

Aspirin has one of the strongest prevention signals in the whole oncology literature for hepatocellular carcinoma, or HCC.

That matters because HCC is unusual. The at-risk population is often identifiable years in advance. Chronic hepatitis B, chronic hepatitis C, MASLD, alcoholic liver disease, and fibrosis all create a recognisable pre-cancer window. That makes aspirin more than a general anticancer question here. It becomes a possible liver-disease prevention discussion. Read the review

This page is also especially relevant in Australia because a major NHMRC-funded clinical trial is now testing aspirin prospectively in chronic liver disease. Read the Curtin University announcement

Overview

HCC develops mainly on a background of chronic hepatic inflammation, fibrosis progression, and repeated liver-cell injury.

That makes it a strong mechanistic fit for aspirin. Aspirin may interrupt HCC development at several earlier steps, including COX-2 / PGE2 signalling, platelet-driven sinusoidal injury, fibrogenic signalling, and immune escape. Read the meta-analysis

The most important practical feature of the HCC literature is this:

duration matters.

The strongest protection usually appears after 5 years or more of continuous low-dose use. That makes HCC a poor fit for short-term aspirin thinking and a much better fit for long-horizon prevention in defined liver-risk groups. Read the AASLD summary

Key human data

Prevention in chronic viral hepatitis

The strongest current data comes from people with chronic hepatitis B or C.

• Swedish National Registry: In 50,275 adults with chronic viral hepatitis followed for a median of about 8 years, aspirin users had about 31% lower relative risk of developing HCC than non-users. Read the summary

• The same study showed a clear duration-response pattern. Compared with short-term use, HCC risk was about 10% lower at 1 to 3 years, 34% lower at 3 to 5 years, and 43% lower after 5 or more years. Read the summary

• Liver-related death was also lower, at 11.0% in aspirin users versus 17.9% in non-users over 10 years. Read the summary

• Importantly, this study did not detect a significant increase in GI bleeding in that viral-hepatitis population. Read the summary

That safety point matters, but it should not be overgeneralised to all cirrhotic patients. Advanced portal-hypertension populations remain a more delicate question.

Harvard and Massachusetts General Hospital cohorts

A 2018 analysis of two long-running US prospective cohorts also supported lower HCC risk with regular aspirin use.

The association was stronger with more regular use and especially after 5 or more years of exposure. Read the Harvard summary

That fits the Swedish viral-hepatitis data closely.

AASLD 2018 liver-meeting analysis

The major AASLD presentation reinforced the same core message.

HCC risk reduction emerged most clearly after at least 5 years of regular aspirin use. Shorter use did not appear to offer the same benefit. Read the AASLD summary

That duration threshold is now one of the most consistent features of the HCC aspirin literature.

Meta-analysis across all studies

A 2023 pooled analysis found that aspirin use was associated with about 30% lower HCC risk overall. Read the meta-analysis

The same review also showed an important limit.

In the subgroup with cirrhosis, including more than 120,000 patients, the signal was weaker and no longer clearly significant. That suggests aspirin may work best earlier, in the pre-cirrhotic or fibrosis-progressing window rather than after cirrhosis is fully established. Read the meta-analysis

That is clinically important.

It suggests aspirin may be most useful while hepatic inflammation and fibrogenesis are still modifiable.

MASLD — the fast-growing risk group

The MASLD story is newer and still evolving.

• A JAMA trial in 2024 reported that low-dose aspirin reduced hepatic fat content in MASLD patients. Read the trial

• Observational studies also suggest lower fibrosis progression, lower HCC incidence, and lower liver-related mortality in some MASLD populations. Read the paper

• But a 2025 follow-up study in MASLD did not find a significant reduction in overall mortality or liver-related events over 3 years. Read the paper

That mixed picture likely reflects time horizon.

Aspirin may need longer exposure to influence HCC risk meaningfully in MASLD, just as it seems to in viral hepatitis.

PD-L1 reduction

A particularly important newer mechanistic finding is that aspirin has been shown to reduce PD-L1 expression in HCC.

That matters because PD-L1 is a key immune-evasion pathway in liver cancer, and it also makes aspirin a biologically interesting partner for checkpoint-based strategies. Read the paper

The Australian clinical trial

This is one of the most important active aspirin trials for this whole section.

The study is led by Professor John Olynyk at Curtin Medical School in Perth and is funded by more than $5 million through an NHMRC Clinical Trials and Cohort Studies Grant. Read the announcement

Key details:

• Design: A 5-year prospective clinical trial

• Population: People with chronic liver disease

• Aim: Test whether aspirin can safely reduce HCC risk in higher-risk liver-disease patients

This matters because observational evidence is already strong enough to justify a prospective answer, but not yet strong enough for routine guideline-level adoption in all chronic-liver-disease settings.

For Australian readers especially, this is one of the most directly relevant active trials in the whole aspirin topic.

Mechanistic relevance

COX-2, inflammation, fibrosis, and carcinogenesis

The HCC sequence is strongly inflammation-driven.

Chronic liver injury activates hepatic stellate cells, increases COX-2, and drives PGE2 production. That promotes hepatocyte survival, immune escape, and fibrosis progression. Read the review

Aspirin may interrupt this sequence at several steps at once:

• lower COX-2 / PGE2 activity

• less inflammatory pressure

• less fibrogenic signalling

• less oncogenic progression over time

That is why HCC looks more like a true carcinogenesis-interruption page than many other aspirin pages.

Platelet-driven liver injury

Platelets are not passive in chronic liver disease.

Platelet activation within hepatic sinusoids contributes to microvascular inflammation and stimulates stellate-cell activity, which feeds fibrosis progression. Aspirin's COX-1 / TXA2 blockade may reduce part of this platelet-driven liver injury. Read the review

That gives HCC a second aspirin logic beyond tumour-cell signalling alone.

TXA2, ARHGEF1, and T-cell suppression in the liver

The 2025 Nature study adds more weight here because it specifically showed that T cell-specific ARHGEF1 deletion increased immune-mediated rejection of liver metastases. Read the repository version

That does not prove aspirin prevents HCC through that mechanism alone.

But it does confirm that the TXA2 → ARHGEF1 → CD8-positive T-cell suppression axis is active in the hepatic immune environment. That is highly relevant in a liver cancer shaped by immune escape.

For the broader mechanism, see Aspirin and Thromboxane A2 (TXA2).

PD-L1 suppression and checkpoint logic

Because aspirin lowers PD-L1 expression in HCC, it also becomes interesting as a possible immunotherapy-combination partner.

That is biologically relevant in an era where atezolizumab plus bevacizumab is already a major first-line regimen in advanced HCC. This remains mechanistic rather than clinical proof, but the logic is strong. Read the paper

Clinical positioning

A critical caution

HCC is one of the strongest aspirin pages.

It is also one of the most safety-sensitive.

Patients with advanced cirrhosis, portal hypertension, oesophageal varices, or major coagulopathy can have a much higher baseline bleeding risk. That means the reassuring viral-hepatitis data should not be applied casually to all advanced liver-disease patients. Read the Curtin announcement

For earlier chronic liver disease, such as viral hepatitis or MASLD without advanced fibrosis, the prevention discussion is more straightforward, but still needs clinical guidance.

Practical interpretation

This page is most useful for readers with:

• chronic hepatitis B or C

• MASLD or metabolic liver-disease risk

• known fibrosis progression

• family or clinician concern about HCC risk

The most useful questions for a hepatologist or oncology team are:

1. What stage is my liver disease — inflammation, fibrosis, or established cirrhosis?

2. Do I have chronic hepatitis B or C, where the prevention signal is strongest?

3. Do I have MASLD, and is fibrosis progression already documented?

4. Am I potentially eligible for the current Curtin / NHMRC aspirin trial?

5. Given liver function, platelet status, and bleeding risk, is low-dose aspirin safe enough to discuss?

That is where the HCC aspirin page becomes genuinely practical.

References

• Swedish registry data — lower HCC risk and lower liver-related mortality in chronic viral hepatitis, with duration-response pattern. Read the summary

• 2023 meta-analysis — about 30% lower HCC risk overall, with weaker cirrhosis subgroup signal. Read the meta-analysis

• Harvard and MGH cohort analysis — dose- and duration-dependent lower HCC risk. Read the Harvard summary

• AASLD 2018 liver-meeting summary — benefit strongest after 5 or more years of use. Read the summary

• JAMA 2024 MASLD trial — low-dose aspirin and lower hepatic fat content. Read the trial

• 2025 review on aspirin and HCC prevention in MASLD. Read the review

• 2025 MASLD follow-up study with null short-term mortality and liver-event findings. Read the paper

• Curtin University and NHMRC trial announcement — prospective Australian clinical trial in chronic liver disease. Read the announcement

• Yang et al., Nature 2025 — TXA2, ARHGEF1, and liver-metastasis immune biology. Read the repository version

• Review of aspirin mechanisms in HCC, fibrosis, and platelet biology. Read the review

• 2025 review covering aspirin and PD-L1-related HCC biology. Read the paper

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form